Anne Barton

Jul 8, 2024 | acrjournals.onlinelibrary.wiley.com | Sizheng Zhao |Kimme Hyrich |Zenas Yiu |Anne Barton

INTRODUCTION Inhibitors of the interleukin 13 (IL-13) pathway, such as dupilumab (dual interleukin 4 [IL-4]/IL-13 inhibitor), tralokinumab, and lebrikizumab (pure IL-13 inhibitors), were developed to treat atopic diseases including atopic dermatitis, chronic rhinosinusitis, and asthma.1-4 Musculoskeletal adverse events resembling seronegative spondyloarthritis have been reported after dupilumab initiation, but evidence is limited to case series and spontaneous pharmacovigilance with uncertain...